| Jingyan Wang,Linzhi Zhang,Xiaoming Peng,Yun Zhao,Lin Zhou. Combination of TACE and FOLFOX4 in the treatment of unresectable advanced hepatocellular carcinoma: a prospective cohort study. Oncol Transl Med, 2020, 6: 208-216. |
| Combination of TACE and FOLFOX4 in the treatment of unresectable advanced hepatocellular carcinoma: a prospective cohort study |
| Received:April 10, 2020 Revised:October 12, 2020 |
| View Full Text View/Add Comment Download reader |
| KeyWord:advanced hepatocellular carcinoma; transcatheter arterial chemoembolization (TACE); FOLFOX4 |
| Author Name | Affiliation | E-mail | | Jingyan Wang | The Fifth Medical Center of PLA General Hospital | wangjingyan.yan@163.com | | Linzhi Zhang | The Fifth Medical Center of PLA General Hospital | | | Xiaoming Peng | The Fifth Medical Center of PLA General Hospital | | | Yun Zhao | The Fifth Medical Center of PLA General Hospital | | | Lin Zhou | The Fifth Medical Center of PLA General Hospital | lindagery302@163.com |
|
| Hits: 6891 |
| Download times: 7953 |
| Abstract: |
| Objective: The aim of the study was to assess the effectiveness and safety of a combined therapy with
transcatheter arterial chemoembolization (TACE) and FOLFOX4, in patients with unresectable advanced
hepatocellular carcinoma (HCC).
Methods: In this study, patients with advanced HCC, that received treatment between November 2015
and October 2017, were recruited. Among these, 30 patients were treated with TACE only (TACE group);
whereas 33 patients were treated with a combination of FOLFOX4 chemotherapy and TACE (combination
group). Survival analyses, including overall survival (OS) and progression free survival (PFS) analysis,
were performed for both groups. Following this, the responses of patients to treatment were evaluated
every 3 months, and the toxic and adverse events were observed.
Results: The median follow-up time was 9.2 months (3–36 months). In the combination group, at 3
months, a disease control rate (DCR) of 60.6%, and a median OS of 9.1 months was obtained [95%
confidence interval (CI) 6.5–11.7]. In the TACE group, the DCR and OS were 33.3% and 5.5 months (95%
CI 4.3–6.7), respectively. On the other hand, the PFS in the combination and TACE groups were observed
as 5.6 months (95% CI 3.6–7.6) and 2.6 months (95% CI 2.0–3.2), respectively. Both these findings
indicate a statistically significant difference (P = 0.01) between both the groups. Similar TACE associated
adverse events were observed in both groups. In the combination group, frequently observed FOLFOX4
related adverse effects included nausea (90.9%), leukopenia (75.8%), thrombocytopenia (69.7%), and
vomiting (69.7%). Most adverse reactions were between grades I–III and were alleviated after symptomatic
treatments.
Conclusion: The combination of TACE with FOLFOX4 therapy has better effectivity and safety than
TACE alone. |
| Close |
|
|
|